Can't Miss Webinar—Lupus Nephritis: The ACR Guideline in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: fever

Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug

Matthias Blamont & Michael Erman  |  

PARIS (Reuters)—Sanofi SA will be able to provide millions of doses of hydroxychloroquine (HCQ) for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive tells Reuters on Thursday. Paul Hudson, who became CEO of the French drugmaker in September, said in an…

The Personal Side of COVID-19: Q&A with Philip A. Waller, MD

  |  

The outbreak of the SARS-CoV-2 virus is disrupting rheumatology clinics and practices all over the world. In the U.S., many providers are turning to telemedicine to care for their patients, but struggles remain. Philip A. Waller, MD, who practices at Accurate Clinical Research, Houston, spoke with The Rheumatologist about how the pandemic is affecting his…

New Options Emerge for Treating Macrophage Activation Syndrome

  |  

ATLANTA—Macrophage activation syndrome (MAS), a subset of hemophagocytic lymphohistiocytosis (HLH) disease, can be a fatal result of rheumatic disease. But there’s good news: New therapeutic options for refractory MAS targeting individual cytokines are emerging. At the 2019 ACR/ARP Annual Meeting, possible therapeutic options were presented during a pediatric-focused clinical and translational research track, Therapeutic Approaches…

Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

  |  

ATLANTA—Managing pediatric patients with rheumatic disease involves special considerations, such as developmental concerns and physiological traits that may affect dosing of medications, according to two experts. During a session at the 2019 ACR/ARP Annual Meeting, Courtney Kremer, ARNP, a pediatric nurse practitioner at the University of Iowa Stead Family Children’s Hospital, Iowa City, and Jessica…

Coding Corner Questions: Using NP/PA Services in Practice

  |  

Scenario 1: Direct Billing A 70-year-old female patient with rheumatoid arthritis in multiple joints and positive rheumatoid factor returns to the practice for her fourth infusion of infliximab with the nurse practitioner (NP). She reports no fevers, cough, dyspnea or concurrent illness. She rates the severity of her joint pain at 6 on a 10-point…

Remembering Etanercept & the Advent of the Biologic Era

Robert S. Katz, MD  |  

As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…